Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase

  • Junko Watanabe
  • Shinichi Makita
  • Yuta Ito
  • Shunsuke Hatta
  • Tomotaka Suzuki
  • Sayako Yuda
  • Akiko Miyagi Maeshima
  • Suguru Fukuhara
  • Wataru Munakata
  • Tatsuya Suzuki
  • Dai Maruyama
  • Sung-Won Kim
  • Koji Izutsu
Letter to the Editor

Notes

Compliance with ethical standards

Conflict of Interest

JW, SM, YI, SH, ToS, SY, AMM, SF, WM, TaS, and SWK declare no conflicts of interests. DM has received personal fees from Takeda, Janssen, Eisai, Biomedis International, Celgene, Sanofi, Kyowa Hakko Kirin, Fujifilm, Mochida, Ono, Mundipharma, and Chugai; and research finding from GlaxoSmithKline, SERVIER, Abbvie, MSD, Kyowa Hakko Kirin, Ono, and Chugai, outside the submitted work. KI has received personal fees from Kyowa Hakko Kirin, Bristol-Myers, and Shionogi, outside the submitted work.

Research involving humans or animals

Not applicable

Informed consent

Written informed consent was obtained from the patient.

References

  1. 1.
    Makita S, Tobinai K (2017) Clinical features and current optimal management of natural killer/T-cell lymphoma. Hematol Oncol Clin North Am 31:239–253CrossRefPubMedGoogle Scholar
  2. 2.
    Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K (2009) Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594–5600CrossRefPubMedGoogle Scholar
  3. 3.
    Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410–4416CrossRefPubMedGoogle Scholar
  4. 4.
    Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351–2356CrossRefPubMedGoogle Scholar
  5. 5.
    Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K (2005) Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 130:860–868CrossRefPubMedGoogle Scholar
  6. 6.
    Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST, Asian Oncology Summit (2009) Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1093–1101CrossRefPubMedGoogle Scholar
  7. 7.
    Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, Yoon DH, Tang T, Cho J, Park S, Ko YH, Kim SJ, Suh C, Lin T, Kim WS (2017) Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol 28:2199–2205CrossRefPubMedGoogle Scholar
  8. 8.
    Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS (2009) Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 27:6027–6032CrossRefPubMedGoogle Scholar
  9. 9.
    Michot JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V (2015) Concurrent etoposide, steroid, high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. Eur J Cancer 51:2386–2395CrossRefPubMedGoogle Scholar
  10. 10.
    Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, Kojima H, Sobue R, Matsui T, Ino T (1994) Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki 35:635–641PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Junko Watanabe
    • 1
  • Shinichi Makita
    • 1
  • Yuta Ito
    • 1
  • Shunsuke Hatta
    • 1
  • Tomotaka Suzuki
    • 1
    • 2
  • Sayako Yuda
    • 1
    • 3
  • Akiko Miyagi Maeshima
    • 3
  • Suguru Fukuhara
    • 1
  • Wataru Munakata
    • 1
  • Tatsuya Suzuki
    • 1
  • Dai Maruyama
    • 1
  • Sung-Won Kim
    • 2
  • Koji Izutsu
    • 1
  1. 1.Department of HematologyNational Cancer Center HospitalTokyoJapan
  2. 2.Department of Hematopoietic Stem Cell TransplantationNational Cancer Center HospitalTokyoJapan
  3. 3.Department of PathologyNational Cancer Center HospitalTokyoJapan

Personalised recommendations